Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, Genaissance, Tokyo Women s Medical University, DeCode, Emory Medical School, Roche, St. Luke s Health System, US Armed Forces Institute of Pathology, Transgenomic, Qiagen, Ingenium, Cepheid


Sequenom Inks Gene-Expression Deals with TIGR, U Michigan

The Institute for Genomic Research will use Sequenom’s MassArray benchtop system to study the way genetic polymorphisms functionally impact gene expression, Sequenom said this week.

Additionally, the University of Michigan Medical Center has purchased Sequenom’s MassArray 7K system, which is designed to enable quantitative detection of low-copy-number genes. The Pediatrics and Human Genetics department is using this system, according to Sequenom.

Genaissance Pens PGx Deal With Ferring Pharmaceuticals …

Genaissance Pharmaceuticals will provide Ferring Pharmaceuticals certain pharmacogenomic services and technology, the companies said last week.

Terms of the agreement call for Genaissance to provide Ferring its DNA banking services through its Morrisville, NC, facility. Genaissance will also collaborate with Ferring to identify clinical projects for the application of its HAP technology.

… And Licenses HAP Service To Japanese Medical School

Genaissance Pharmaceuticals will provide its haplotyping services to the Tokyo Women’s Medical University for use in drug-response studies, the company said last week.

The deal represents the first fruits in a marketing partnership signed between Genaissance and Tokyo-based Intec Web and Genome Informatics Corporation in February 2002.

“We believe numerous Japanese government agencies and pharmaceutical companies plan to conduct genetic variation research over the next few years. We plan to capitalize on those opportunities,” Munehiro Sueoka, president of Intec, said in a statement.

DeCode, Emory Medical School To Research Sleep Disorders

DeCode Genetics will help Emory University’s medical and nursing schools to research sleep disorders with the goal of developing new drugs, the university said last week.

The collaboration is an extension of a partnership DeCode and Emory penned in 2002 to test whether the company’s genotyping discoveries in Iceland can be applied to a more diverse population.

The new deal will use the same model to determine whether genes linked to certain types of sleep disorders in Icelandic patients are responsible for similar problems in the US heterogeneous population, Emory said.

Roche, St. Luke’s Establish Molecular Diagnostics Center in Kansas City

Saint Luke’s Health System and Roche Diagnostics will establish a Molecular Center of Excellence to perform molecular diagnostic testing using Roche’s PCR technology and other genomic platforms.

Saint Luke’s, based in Kansas City, said the five-year collaboration will improve its diagnostic services “by providing more sensitive, more specific, and faster results so that patient treatment can be improved.” Financial terms of the agreement were not provided.

US Defense Lab Selects Third Wave Reagents for CF Screening

The US Armed Forces Institute of Pathology will use Third Wave Technologies’ Invader cystic fibrosis analyte-specific reagents to screen US military personnel for genetic mutations associated with CF, the company said last week.

“We expect the number of [CF] test requests to double or triple as more and more Army facilities seek out our expertise,” Jack Lichy, director of the AFIP Molecular Diagnostics Laboratory, said in a statement. The AFIP is the central reference laboratory for the Army, Navy, Air Force, Public Health Service, and Department of Veterans Affairs.

Transgenomic Secures $7.5M in Revolving Credit

Transgenomic has secured a $7.5 million revolving line of credit with Laurus Master Fund, the company said last week.

The arrangement replaces an earlier line worth $5 million from a commercial bank that offered a higher interest rate, the company said.

In August, Transgenomic raised $4.5 million in a private stock placement with a number of investors.

Qiagen to Integrate Sample Prep Products Into Artus’ Molecular Dx

Artus will integrate the nucleic acid sample-prep products made by Qiagen’s German subsidiary into its infectious disease-diagnostic systems, the companies said last week.

Terms of the agreement call for Artus, based in Hamburg, Germany, to fold versions of Qiagen’s QiAmp technology into its custom diagnostic tools, which include systems for the detection of diseases such as SARS, herpes simplex, EBV, West Nile virus, malaria, and salmonella.

The systems use Artus’ RealArt technology, which is based on PCR technology that Artus has licensed from Roche, according to the companies. The companies did not disclose the financial terms of the agreement.

Ingenium Closes €13.8M Round of VC Financing

Ingenium Pharmaceuticals has raised €13.8 million ($16.8 million) in a third round of private-equity financing, the company said last week.

New investor HBM BioVentures and prior Ingenium investors TVM Techno Venture Management and Polaris Venture Partners led the round. Pitching in were Ascenion, Index Ventures, IKB, Schroder Ventures Life Sciences, and Sofinnova Partners.

Cepheid Wins US Patent for Use With RT-PCR Technology

Cepheid has won a US patent that provides the ability to heat and cool components of real time PCR, the company said last week.

US Patent No. 6,660,228 is called “Apparatus for performing heat-exchanging, chemical reactions.”

Filed under

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.